The Laboratory of Malaria Immunology and Vaccinology (LMIV), formerly The Malaria Vaccine Development Branch (MVDB), is an NIAID initiative working in close collaboration with DMID to respond to the global need for vaccines against malaria. The mission of the LMIV is to discover and develop malaria vaccines through fundamental and clinical research in immunobiology and vaccinology, including investigations of malaria pathogenesis in the context of host immune responses. In support of this mission, the LMIV will develop new assays and animal models to assess vaccine candidates. Development of vaccine candidate AMA1-C1/ISA720 was terminated due to concerns on related local reactogenicity, and lack of long-term stability of the formulation.
|Zhu, Daming; McClellan, Holly; Dai, Weili et al. (2011) Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine. Vaccine 29:3640-5|
|Ellis, Ruth D; Sagara, Issaka; Doumbo, Ogobara et al. (2010) Blood stage vaccines for Plasmodium falciparum: Current status and the way forward. Hum Vaccin 6:|
|Pierce, Mark A; Ellis, Ruth D; Martin, Laura B et al. (2010) Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Vaccine 28:2236-42|